Skip Navigation

European Heart Journal 1999 20(18):1287-1289; doi:10.1053/euhj.1998.1726
Copyright © 1999 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rydén, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rydén, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

ACE inhibitors or AT1receptor blockers in heart failure?

L. Rydéna

a Karolinska Hospital, Stockholm, Sweden

1999

References

  1. Unger T, Culman J, Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens. 1998;16:S3–9
  2. Parmley WW. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med. 1998;105:27S–31S[Medline]
  3. Nakajima M, Hutchinson HG, Fujinaga M. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1receptor: gain-function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92:10663–10667[Abstract/Free Full Text]
  4. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A. 1996;93:156–160[Abstract/Free Full Text]
  5. Stoll M, Steckelings UM, Bottari SP, Metzger R, Unger T. The angiotensin AT2receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651–657[Web of Science][Medline]
  6. Husain A. The chymase-angiotensin system in humans: editorial review. J Hypertens. 1993;11:1155–1159[Web of Science][Medline]
  7. Wollert KC, Drexler H, Just H. Differential effects of kinins of cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation. 1997;95:1910–1917[Abstract/Free Full Text]
  8. Wolny A, Clozel J-P, Rein J. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219–227[Abstract/Free Full Text]
  9. Richer-Guidicelli C, Fornes P, Cazaubon C, Nisato D, Guidicelli J-F. Effects of angiotensin II AT1receptor blockade on survival, systemic and coronary hemodynamics and cardiac remodelling in postischaemic heart failure in rats. Circulation. 1997;96:3605[Web of Science]
  10. N Engl J Med. 1987;316:1429–1435[Abstract]
  11. Cohn JN, Johnson G, Ziesche S. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310[Abstract]
  12. N Engl J Med. 1991;325:293–302[Abstract]
  13. N Engl J Med. 1992;327:685–691[Abstract]
  14. Pfeffer MA, Braunwald E, Moyé LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med. 1992;327:669–677[Abstract]
  15. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83:1A–38A[CrossRef][Web of Science][Medline]
  16. Pitt B, Segal R, Martinez FA. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–752[CrossRef][Web of Science][Medline]
  17. McKelvie R, Yusuf S, Pericak D, Held P. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD pilot study). Eur Heart J. 1998;19:133
  18. Eur Heart J. 1997;18:1457–1464[Abstract/Free Full Text]
  19. Hobbs FDR, Wilson S, Jones MI. European survey (EuroHF) of primary care physician perceptions and practice in heart failure diagnosis and management (Abstr). Eur Heart J. 1998;19:248
  20. Andersson F, Cline C, Rydén-Bergsten T, Erhardt L. Angiotensin Converting Enzyme (ACE) Inhibitors and Heart Failure: The Consequences of Underprescribing. Pharmacoeconomics. 1999;15:535–550[CrossRef][Web of Science][Medline]
  21. Packer M, Poole-Wilson P, Armstrong P. Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic heart failure: the Assessment of Treatment with Lisinopril And Survival Study (ATLAS) (Abstr). Eur Heart J. 1998;19:142
  22. Lancet. 1999;353:9–13[CrossRef][Web of Science][Medline]
  23. Hjalmarson, A
  24. Am J Cardiol. 1996;78:902–907[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rydén, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rydén, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?